# Pizarra — PT-pseudo_2eef4115a253 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2eef4115a253
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 59-year-old male
  - PSA: 2.11 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.058 ng/mL²
  - PSA velocity: -0.04 ng/mL/yr
  - Prior PSA: 2.1 ng/mL
  - Prostate volume: 36.08 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7737494 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 2.11 ng/mL. PI-RADS 4. PSAD 0.06. Prostate volume 36 mL. csPCa 0.77.

Vitals: weight 85 kg, height 182 cm, BMI 25.7, BP 117/84 mmHg, HR 73 bpm. Smoking: Ex-smoker (36 pack-yr, quit 2021).

Chief complaint: Evaluation requested after imaging revealed a left peripheral zone abnormality alongside a recent PSA elevation.

History: At 59 years of age, the patient works as a retired shopkeeper. He is divorced and currently resides with his partner. A former smoker, he accumulated 36 pack-years before cessation in 2021. Daily activity remains largely sedentary, punctuated by brief walks. Moderate voiding complaints dominate the history, specifically nocturia and a diminished urinary stream, correlating with an IPSS score of 19. He explicitly denies haematuria or pelvic discomfort. No chronic comorbidities exist, and he takes no active medications. Alcohol intake averages two units per week. An Arabic interpreter will be required during the consultation to facilitate precise dialogue.

Physical examination: DRE — texture: symmetrically smooth; consistency: normal; asymmetry: absent; nodules: none. Vital parameters remain stable, recording a blood pressure of 117/84 mmHg alongside a regular heart rate of 73 bpm. Thoracic auscultation reveals clear lung fields, and no peripheral oedema is observed.

Patient info: retired shopkeeper; Divorced; Lives with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 2 units / week; exercise Sedentary lifestyle, occasional walking; IPSS score: 19/35 (moderate LUTS).

Recent other appointments: Dermatology — actinic keratosis check; Pulmonary function test — known COPD follow-up; Vascular surgery — varicose veins consult.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.77 +/- 0.16   (95% CI 0.39-0.98)

Where the uncertainty comes from:
  - aleatoric  dA = 0.13  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.10  (few labelled cases resemble this one)
  - 7.3 effective neighbours out of 10; 4 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=0.0, psa=2.11, age=59.0, psad=0.058, dre_ord=0.0, vol=36.08, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=4, PSA=2.11, csPCa probability=0.77) and failed to incorporate the PSA velocity (-0.04 ng/mL/yr), the PSA density (0.058 ng/mL²), and the patient's history of moderate LUTS (IPSS 19).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a high csPCa probability (0.77), but this ignores the context that the patient is biopsy-naive and the DRE is normal. Furthermore, the prior's uncertainty interval (0.77 +/- 0.16) is wide, suggesting the model is highly uncertain, which could mean the underlying data distribution is poorly represented for this specific profile. The guideline criterion suggests deferral if clinical suspicion is low (PSA density < 0.10 ng/mL/cc and no family history), which the prior did not weigh against the low PSA density (0.058 ng/mL²).

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
laboratory panel - to assess the full context of PSA density and other lab values.
previous GP / urology consultation notes - to gauge the clinical suspicion level beyond the calculated csPCa probability.
family-history anamnesis - to assess the family history context mentioned in the guideline criteria.

GUIDELINE ANCHOR
The guideline states that MRI-directed US-guided prostate biopsy is the standard of care when MRI is positive (PI-RADS $\ge$ 4), but it also suggests omitting biopsy when clinical suspicion is low (PSA density $< 0.10 \text{ ng/mL/cc}$ and no family history).

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Radboudumc | 28 Jan 2025 | Prostate Multiparametric MRI
The mpMRI report identifies a PI-RADS 4 lesion in the left peripheral zone mid-gland, with a prostate volume of 36.08 mL and a PSA density of 0.058 ng/mL/mL. It notes no seminal vesicle invasion or extracapsular extension.

get_psa_trend
PSA trend shows a rising trajectory: 0.5 ng/mL (Jan 2023) -> 1.7 ng/mL (Sep 2023) -> 1.9 ng/mL (May 2024) -> 2.11 ng/mL (Feb 2025).

get_previous_notes
Previous notes document from 04 Oct 2024 mentions a PSA increase to 2.1 ng/mL and notes moderate LUTS (IPSS 19), leading to the scheduling of an mpMRI.

get_lab_results
Laboratory results show PSA of 2.1 ng/mL on 26 Dec 2024, with a %Free PSA of 17%. Renal function (eGFR >60 mL/min/1.73m2) and other markers are within normal limits.

NOT RETRIEVED
family_history
The family history of prostate cancer was not retrieved, which is needed to fully assess the guideline criterion regarding low PSA density and family history.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling:
- mpMRI shows a PI-RADS 4 lesion in the left peripheral zone.
- PSA trend shows a clear rising trajectory over the last year.
- Previous notes confirm a recent PSA increase and LUTS, justifying the MRI.

AGAINST Sampling:
- DRE findings are Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).
- PSA density is low at 0.058 ng/mL/mL, which aligns with the guideline suggestion for deferral if family history is absent.

WHERE THIS LEANS
The evidence strongly supports proceeding with a biopsy due to the PI-RADS 4 finding on the MRI and the rising PSA trend, despite the low PSA density. This aligns with the guideline criterion for biopsy when PI-RADS is 4 or higher.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision is to proceed with biopsy because the mpMRI identified a PI-RADS 4 lesion, which is the primary driver according to the guideline criterion. This finding was supported by the rising PSA trend and previous notes confirming clinical concern. The low PSA density of 0.058 ng/mL/mL is noted, but the PI-RADS 4 score overrides this context in this biopsy-naive setting. The statistical prior was overturned by the retrieved mpMRI report showing the PI-RADS 4 finding.

Variables that carried weight: age=important, dre=noted, psa=important, vol=noted, psad=decisive, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
